| Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta‐Analysis |
Jinchul Kim1
, Jinhyun Cho1, Sang Eun Yoon2, Won Seog Kim2,3, Seok Jin Kim2,3
|
1Department of Hematology-Oncology, Inha University College of Medicine, Incheon, Korea
2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
|
| Correspondence |
Seok Jin Kim ,Tel: 82-2-3410-1766, Fax: 82-2-3410-1754, Email: kstwoh@skku.edu
|
|
|
Received: December 26, 2022; Accepted: March 8, 2023. Published online: March 13, 2023. |
|
|
|
| ABSTRACT |
Purpose
We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods
R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and CAR T-cell therapy was used as reference treatment.
Results
26 ASCT-eligible cohorts from 17 studies comprising 2924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval (CI) 0.15–0.65) for the CAR T-cell group and 0.34 (95% CI 0.30–0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta‐regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI 0.35–0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI 0.37–0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion
Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting. |
| Key words:
Relapsed/refractory large B-cell lymphoma, Regimen, PFS outcome, Meta-analysis |
|
PDF Links
Full text via DOI
Download Citation 
CrossRef TDM
Supplementary1 
